See more : Comal S.p.A. (CML.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Spectrum Pharmaceuticals, Inc. (SPPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spectrum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Paliburg Holdings Limited (0617.HK) Income Statement Analysis – Financial Results
- Alliance Aviation Services Limited (AQZ.AX) Income Statement Analysis – Financial Results
- Dalian Huarui Heavy Industry Group Co., LTD. (002204.SZ) Income Statement Analysis – Financial Results
- Oji Holdings Corporation (3861.T) Income Statement Analysis – Financial Results
- 5th Planet Games A/S (IDGAF) Income Statement Analysis – Financial Results
Spectrum Pharmaceuticals, Inc. (SPPI)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.11M | 0.00 | 0.00 | 22.62M | 109.33M | 128.37M | 146.44M | 162.56M | 186.83M | 155.85M | 267.71M | 192.96M | 74.11M | 38.03M | 28.73M | 7.67M | 5.67M | 577.00K | 258.00K | 1.00M | 2.37M | 41.11K | 1.00 | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 1.79M | 0.00 | 0.00 | 12.01M | 26.76M | 47.22M | 35.84M | 27.69M | 27.04M | 28.58M | 46.63M | 33.84M | 17.44M | 8.15M | 1.19M | 0.00 | 97.00K | 397.00K | 123.00K | 0.00 | 0.00 | 0.00 | -1.13M | -519.88K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 8.32M | 0.00 | 0.00 | 10.61M | 82.58M | 81.15M | 110.60M | 134.87M | 159.79M | 127.27M | 221.07M | 159.13M | 56.67M | 29.88M | 27.53M | 7.67M | 5.58M | 180.00K | 135.00K | 1.00M | 2.37M | 41.11K | 1.13M | 519.88K | 600.00K | 300.00K | 100.00K |
| Gross Profit Ratio | 82.28% | 0.00% | 0.00% | 46.91% | 75.53% | 63.22% | 75.52% | 82.97% | 85.53% | 81.66% | 82.58% | 82.46% | 76.47% | 78.57% | 95.85% | 100.00% | 98.29% | 31.20% | 52.33% | 100.00% | 100.00% | 100.00% | 112,813,400.00% | 51,987,600.00% | 600.00% | 300.00% | 100.00% |
| Research & Development | 42.20M | 87.30M | 109.38M | 79.33M | 94.96M | 65.90M | 58.94M | 50.77M | 69.66M | 46.67M | 42.54M | 27.72M | 57.30M | 21.06M | 26.68M | 33.29M | 17.87M | 12.60M | 6.95M | 3.68M | 12.73M | 20.61M | 38.77M | 20.06M | 8.50M | 4.50M | 600.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 60.41M | 60.36M | 61.37M | 90.70M | 84.27M | 87.35M | 86.51M | 97.41M | 99.32M | 91.97M | 72.55M | 48.55M | 33.61M | 15.16M | 11.58M | 13.60M | 7.50M | 5.98M | 7.62M | 4.10M | 7.58M | 5.11M | 3.47M | 3.10M | 2.30M | 700.00K |
| Other Expenses | -5.33M | -10.89M | -2.94M | -8.89M | 9.58M | 389.00K | 887.00K | -1.25M | -4.37M | -722.00K | -844.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.02M | 147.70M | 169.73M | 140.70M | 213.75M | 177.81M | 172.23M | 175.60M | 191.36M | 166.06M | 141.25M | 103.99M | 109.57M | 58.39M | 42.00M | 44.87M | 31.47M | 20.10M | 12.94M | 11.31M | 16.83M | 28.19M | 45.00M | 24.04M | 12.10M | 7.00M | 1.30M |
| Cost & Expenses | 82.81M | 147.70M | 169.73M | 140.70M | 240.51M | 225.03M | 208.07M | 203.29M | 218.40M | 194.64M | 187.88M | 137.83M | 127.01M | 66.53M | 43.20M | 44.87M | 31.57M | 20.50M | 13.06M | 11.31M | 16.83M | 28.19M | 43.87M | 23.52M | 11.60M | 6.80M | 1.30M |
| Interest Income | 968.00K | 163.00K | 1.34M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 0.00 | 0.00 | 83.00K | 0.00 | 0.00 | 776.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 998.00K | 0.00 | 0.00 | -5.00M | 340.00K | 6.80M | 9.44M | 9.07M | 8.58M | 2.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 0.00 | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -4.36M | 286.00K | 261.00K | 3.34M | 28.10M | 27.65M | 25.95M | 38.32M | 24.29M | 20.07M | 6.74M | 5.65M | 4.51M | 3.72M | 610.00K | 255.00K | 198.00K | 682.00K | 425.00K | 346.00K | 1.33M | 2.27M | 1.13M | 519.88K | 500.00K | 200.00K | -300.00K |
| EBITDA | -77.06M | -147.70M | -169.73M | -140.70M | -93.50M | -68.62M | -34.80M | -3.66M | -11.65M | -21.58M | 86.57M | 63.69M | -52.40M | -25.45M | -10.33M | -40.08M | -26.28M | -20.52M | -12.38M | -9.81M | -9.92M | -25.68M | -42.74M | -20.78M | -11.20M | -7.20M | -1.50M |
| EBITDA Ratio | -761.91% | 0.00% | 0.00% | -622.14% | -85.52% | -53.46% | -23.76% | -2.25% | -6.23% | -13.85% | 32.34% | 33.01% | -70.70% | -66.93% | -35.94% | -522.41% | -463.18% | -3,556.15% | -4,797.29% | -980.80% | -418.13% | -62,458.85% | -4,273,686,000.00% | -2,077,988,900.00% | -11,200.00% | -7,200.00% | -1,500.00% |
| Operating Income | -72.70M | -147.70M | -169.73M | -144.03M | -131.18M | -96.66M | -61.63M | -40.73M | -31.57M | -38.79M | 79.82M | 55.13M | -52.90M | -28.51M | -19.17M | -37.20M | -25.89M | -19.92M | -12.80M | -10.47M | -17.51M | -28.15M | -43.87M | -23.52M | -11.50M | -6.70M | -1.20M |
| Operating Income Ratio | -718.78% | 0.00% | 0.00% | -636.89% | -119.98% | -75.30% | -42.08% | -25.06% | -16.90% | -24.89% | 29.82% | 28.57% | -71.37% | -74.97% | -66.74% | -484.81% | -456.43% | -3,452.69% | -4,961.24% | -1,046.80% | -738.28% | -68,469.52% | -4,387,369,500.00% | -2,352,312,900.00% | -11,500.00% | -6,700.00% | -1,200.00% |
| Total Other Income/Expenses | -5.36M | -10.73M | -1.60M | 174.20M | 11.17M | -11.37M | -9.20M | -9.65M | -11.96M | 2.15M | -844.00K | -2.91M | 4.01M | 8.74M | 3.70M | 3.14M | 581.00K | 1.28M | 2.00K | 78.00K | -126.50M | -200.69K | -8.70K | -2.22M | 200.00K | 700.00K | 300.00K |
| Income Before Tax | -78.06M | -158.43M | -171.33M | -144.59M | -120.01M | -108.03M | -70.83M | -50.38M | -43.53M | -36.64M | 78.98M | 52.22M | -48.89M | -19.77M | -22.71M | -34.06M | -25.31M | -18.64M | -12.80M | -10.62M | -20.72M | -28.35M | -43.88M | -25.75M | -11.30M | -6.00M | -900.00K |
| Income Before Tax Ratio | -771.78% | 0.00% | 0.00% | -639.37% | -109.77% | -84.15% | -48.36% | -30.99% | -23.30% | -23.51% | 29.50% | 27.06% | -65.96% | -51.99% | -79.04% | -443.90% | -446.18% | -3,231.02% | -4,960.47% | -1,061.90% | -873.80% | -68,957.67% | -4,388,239,700.00% | -2,574,649,400.00% | -11,300.00% | -6,000.00% | -900.00% |
| Income Tax Expense | 46.00K | 4.00K | -60.00K | -9.21M | 1.00K | -16.78M | -2.31M | 406.00K | 2.19M | 25.50M | -15.57M | 3.70M | -43.00K | -421.00K | 997.00K | -3.16M | -2.61M | -1.28M | -514.00K | 85.00K | 3.18M | -315.05K | 2.55M | 2.47M | 100.00K | -500.00K | 100.00K |
| Net Income | -78.10M | -158.44M | -171.27M | -135.39M | -120.01M | -91.25M | -68.51M | -50.79M | -45.72M | -62.13M | 94.55M | 48.52M | -48.84M | -19.05M | -15.47M | -34.04M | -23.28M | -18.64M | -12.29M | -10.39M | -17.63M | -27.83M | -46.43M | -25.99M | -11.60M | -6.20M | -1.00M |
| Net Income Ratio | -772.24% | 0.00% | 0.00% | -598.66% | -109.77% | -71.08% | -46.78% | -31.24% | -24.47% | -39.87% | 35.32% | 25.14% | -65.90% | -50.09% | -53.85% | -443.64% | -410.44% | -3,230.85% | -4,762.02% | -1,039.00% | -743.61% | -67,703.21% | -4,642,728,700.00% | -2,598,990,500.00% | -11,600.00% | -6,200.00% | -1,000.00% |
| EPS | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.61 | 0.94 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| EPS Diluted | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.46 | 0.86 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| Weighted Avg Shares Out | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 58.59M | 53.27M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
| Weighted Avg Shares Out (Dil) | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 64.64M | 57.96M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
7 Hot Penny Stocks Under $1.10 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now
Penny stocks to watch this week. The post Best Penny Stocks To Buy?
SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.
NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals" or the "Company") (NASDAQ: SPPI), in connection...
SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.
NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), in connection with its...
Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium
Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning. The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.
Shareholder Alert: Ademi LLP investigates whether Spectrum Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Assertio
MILWAUKEE , April 25, 2023 /PRNewswire/ -- Ademi LLP is investigating Spectrum (NASDAQ: SPPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Assertio. Click here to learn how to join the action https://www.ademilaw.com/case/spectrum-pharmaceuticals-inc or...
SPPI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Spectrum Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to Assertio Holdings, Inc. is fair to Spectrum shareholders. Under the terms of the agreement, Spectrum shareholders will receive:...
SPPI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Spectrum Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to Assertio Holdings, Inc. is fair to Spectrum shareholders. Under the terms of the agreement, Spectrum shareholders will receive:...
Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?
Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on gut-brain axis connection offers potential alternative to...
Source: https://incomestatements.info
Category: Stock Reports